Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Getting real about valuations in biotech

A lesser known valuation approach for biopharmaceutical products offers project managers and out-licensing biotech companies an edge in budget and license negotiations.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Project valuation with DCF.
Figure 2
Figure 3
Figure 4: Value distribution in licensing deals.

References

  1. 1

    Fernández, P. Valuing real options: frequently made errors. Journal of Financial Transformations, 13, 77–81 (2005).

    Google Scholar 

  2. 2

    Dimasi, J.A. Risks in new drug development: approval success rates for investigational drugs. Clin. Pharmacol. Ther. 69, 297–307 (2001).

    CAS  Article  Google Scholar 

  3. 3

    Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711–715 (2004).

    CAS  Article  Google Scholar 

  4. 4

    Tufts Center for the Study of Drug Development. Outlook 2005. Tufts Outlook Report. (Tufts Center, Medford, MA, USA, 2005).

  5. 5

    Grabowski, H.G. & Vernon, J. The distribution of sales revenues from pharmaceutical innovation. Pharmacoeconomics 18 Suppl 1, 21–32 (2000).

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Supplementary information

Related links

Related links

Related links in Nature Research

https://doi.org/10.1038/June21,2004doi:10.1038/bioent814

Value drivers in licensing deals

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Villiger, R., Bogdan, B. Getting real about valuations in biotech. Nat Biotechnol 23, 423–428 (2005). https://doi.org/10.1038/nbt0405-423

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing